Durable Engraftment and Correction of Genetic Defect in Children with Congenital Amegakaryocytic Thrombocytopenia Following Myeloablative Umbilical Cord Blood Transplantation  by Mahadeo, K.M. et al.
PEDIATRIC DISORDERS
280
PARENTAL AWARENESS AND INTEREST IN HEMATOLOGIC STEM CELL
TRANSPLANT FOR THEIR CHILDREN WITH SICKLE CELL DISEASE
Friedrich, P.M.1, Banholzer, K.2, Kim, F.3, Steinfield, E.3, Lehmann, L.1,
Sprinz, P.3 1Dana Farber / Children’s Hospital Cancer Center, Boston,
MA; 2Boston University School of Public Health, Boston, MA; 3Boston
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Background: Hematopoietic stem cell transplantation (HSCT) is
currently the only curative therapy for sickle cell disease (SCD).
HSCT, however, is not often discussed as a therapeutic option early
in the course of the disease. There is limited data on parental willing-
ness to consider HSCT in symptomatic children with SCD, and vir-
tually no data on their opinions when it comes to asymptomatic or
mildly symptomatic children.
Objectives: To assess parental awareness on the role of HSCT as
potential cure for SCD in the pediatric population, to provide par-
ents with information on the role of HSCT, to gain understanding
of potential barriers to transplant, and to improve our understanding
of main worries about HSCT.
Methods: Prospective, observational study in which parents of chil-
dren with SCD between 2 and 18 years received information on the
role of HSCT in the prevention and management of SCD. The data
collected reflects the parents’ baseline awareness of the role of
HSCT as curative treatment for SCD, their reasons to consider (or
not) transplantation and their initial interpretation of the risks in-
volved.
Results:Majority of parents (81%) had heard about HSCT as treat-
ment option for SCD, but fewer acknowledged availability of cura-
tive treatment (50%) or having considered or discussed it as
a treatment option for their child (48%).Nearly all parents expressed
interest in learning about HSCT as treatment option and found the
information offered valuable (92%). They wished they had heard the
information earlier (83%) and would consider transplant, but pre-
dominantly if their child became sicker (91%); development of neu-
rologic conditions and need for chronic transfusions would influence
their decision most. History of neurologic symptoms, priapism, os-
teonecrosis, or red cell antibodies correlated with parents having
heard about HSCT, but not with actually discussing or considering
this as a treatment option for their child. Of the risks described, in-
fertility and isolation generated most concern. Of note, 80% of par-
ents reported they would consider conceiving another child to find
a suitable donor.
Conclusions:Our preliminary data highlight the importance of ap-
propriately educating parents of children with SCD. Although
HSCT is not a treatment option for all childrenwith SCD, this study
suggests that parents are interested in approaches not yet considered
mainstream and are eager to discuss high risk treatment options such
as HSCT.Table 1. RESULTS: Parental awareness about HSCTas treatment o
Is there a cure for sickle cell disease?
Have you ever heard about stem cell transplantation as a treatment
option for sickle cell disease?
Have you ever discussed or considered stem cell transplantation for your child?
Would you be interested in learning about the role of stem cell transplantation
as a treatment option in sickle cell disease?
Correlation between parental answer and history of symptoms
Is there a CURE for sickle cell disease? Histor
Treatm
At leas
Have you ever HEARD about SCT as a treatment
option for sickle cell disease?
Histor
Treatm
At leas
Have you ever DISCUSSED or considered SCT for
your child?
Histor
Treatm
At leas
*Includes neurologic symptoms, priapism, osteonecrosis, or antibodies.
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PLANTATION
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Background: Congenital Amegakaryocytic Thrombocytopenia
(CAMT) is a rare but potentially fatal pediatric disease that can be
cured by hematopoietic stem cell transplantation (HSCT). Success-
ful utilization of unrelated cord blood donors will extend the curative
potential of HSCT to most children with CAMT.
Methods: Retrospective review of all HSCTs performed at Duke
between 1994 and 2010 revealed five children (3 females, 5 Cauca-
sian) transplanted for CAMT. All had absent or markedly decreased
megakaryocytes in bone marrow (BM), elevated thrombopoietin
level and normal cytogenetics with no evidence of other BM failure
syndrome, including Fanconi anemia. Homozygous C-MPLmuta-
tion was detected in one patient. BM in 3 showed dysplasia. Prior
treatments included IVIG (n 5 4), steroids (n 5 3), or Danazol
(n 5 1). Cord blood units (CBU) from unrelated (n 5 4) or sibling
(n 5 1) donors were used. CBU were 4/6 (n 5 3), 5/6 (n 5 1) or 6/
6 (n 5 1) matched by low resolution for HLA-A and B and
high resolution DRB1. All received myeloablative conditioning
with Busulfan/Cyclophosphamide/ATG. In one patient, cyclo-
phosphamide was partially substituted with Melphalan due to
cardiomyopathy.
Results: Children were diagnosed at median age of 18 months
(range, 2-30) and transplanted at median age of 31 months (range,
13-60). Median (range)/Kg of cryopreserved total nucleated cell
(TNC), reinfused TNC, CD34, and CFU doses were 8(6-12.5)
x10e7, 7.3(6.1-9.3)x10e7, 1.8(.2-13.6)x10e5, and 6.8(3.3-22.4)
x10e4, respectively. All patients engrafted with median (range)
time to neutrophil and platelet engraftment being 19 days (14-
19) and 36 days (22-41), respectively. Grades II-IV acute GvHD
developed in 3 (II, n 5 1; III, n 5 2) and chronic GvHD in
none. Two patients developed auto-immune hemolytic anemia
requiring temporary transfusion support but both resolved with
steroid therapy. At a median follow-up of 10 years (range 0.16
to 16), all patients are alive with normal platelet counts (median
262k/uL, range 176-438k/uL), . 98% donor chimerism and
Lansky scores of 100%.
Conclusions: Cord blood transplantation from unrelated or
related donors following myeloablative chemotherapy based condi-
tioning corrects thrombocytopenia and results in sustainable high-
level donor chimerism and excellent survival outcomes among
patients with CAMT. This approach should be considered shortly
after diagnosis for these patients to maximize curative results with
HSCT.ption for SCD
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